TD Cowen analyst Charles Rhyee upgraded Veeva (VEEV) to Buy from Hold with a price target of $380, up from $297. The company is well positioned to post sales growth above consensus estimates due to multiple drivers, including the secular shift to large pharma insourcing and the Iqvia (IQV) partnership, the analyst tells investors in a research note. TD expects Veeva shares to re-rate moving forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Strong Market Position and Growth Potential Justify Buy Rating
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- Veeva says Bristol Myers commits to Veeva Vault CRM
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Veeva Systems: Strategic Positioning and Growth Potential Justify Buy Rating